Johnson & Johnson (JNJ) Asset Writedowns and Impairment (2009 - 2026)

Johnson & Johnson has disclosed Asset Writedowns and Impairment across 18 years of filings, most recently posting -$8.0 million for Q1 2026.

• Asset Writedowns and Impairment for Q1 2026 came in at -$8.0 million, down 100.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $200.0 million (down 50.12% YoY), and the FY2025 annual result was $204.0 million, down 49.63% from the prior year.
• Asset Writedowns and Impairment came in at -$8.0 million for Q1 2026 at Johnson & Johnson, down from $81.0 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $820.0 million in Q4 2023 to a low of -$981.0 million in Q1 2023.
• The 5-year median for Asset Writedowns and Impairment is $81.0 million (2025), against an average of $117.3 million.
• Across the five-year window, Asset Writedowns and Impairment surged 4792.31% in 2022 and tumbled 100.0% in 2026, its largest moves.
• Johnson & Johnson's Asset Writedowns and Impairment stood at $610.0 million in 2022, then slipped by 22.13% to $475.0 million in 2023, then slumped by 94.53% to $26.0 million in 2024, then jumped by 211.54% to $81.0 million in 2025, then slumped by 109.88% to -$8.0 million in 2026.
• The last three Asset Writedowns and Impairment figures came in at -$8.0 million (Q1 2026), $81.0 million (Q4 2025), and $93.0 million (Q3 2025), per Business Quant data.